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Abstract
Cerebral cavernous malformations (CCM) are a group of homogenous lesions in
the brain, spinal cord and retina that consist of focal sinusoidal dilatations of vasculature
which can lead to devastating life-altering and/or life-ending events such as seizure and
hemorrhagic stroke. CCM exhibit compromised blood brain barrier due to perturbed
endothelial cell to endothelial cell tight junctions, resulting in chronic hemorrhage.
Linkage analysis has led to the identification of three loci which segregate to familial
CCM (CCM1, CCM2 and CCM3). Previous studies have identified PDCD10 as the gene
responsible for CCM3. Recent in vitro data have implicated PDCD10 in apoptosis and
cell proliferation.
Preliminary in vitro experiments demonstrate an increase in apoptosis after
overexpression of PDCD10. Introduction of mutations found in human CCM into the
above expression vector failed to increase apoptosis. Human umbilical vein endothelial
cells (HUVECs) exposed to conditions of serum deprivation increased expression of
CCM3 which preceded an increase in cleaved caspase-3. Conversely, inhibition of
PDCD10 expression through siRNA led to a decrease in cell death. These experiments
have been helpful in evaluating CCM3 function in vitro. To assess the role of CCM3 in
vivo, we have tissue-specifically knocked-out CCM3 utilizing Cre-recombinase mediated
recombination of loxP-flanked CCM3 in mice. Tie2 and GFAP promoters were used to
drive Cre expression in endothelial cells and astrocytes respectively. Our results indicate
that CCM3 is important in the endothelium for early vascular development. These
mutant embryos exhibited morphology similar to that of CCM1 knockout mice. Mice
deficient in CCM3 in astrocytes exhibited dysmorphic features, such as an enlarged brain
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and smaller body habitus when compared with control mice. Histologically, cortical
layering was perturbed in the mutant mice. BrdU assays suggest that there is a decrease
in dividing cells present in the superficial layers of the cortex. Analysis of one adult
mutant survivor led to the discovery of a CCM present near the cerebellar-pontine angle.
Isolation of astrocytes from GFAP mutant mice revealed similar characteristics to our
previous siRNA experiments using HUVECs. Mutant astrocytes were resistant to
cycloheximide induced apoptosis as measured by flow cytometry. Our results support
the current hypothesis that PDCD10 is a promoter of apoptosis. These results also
suggest that astrocytes play a critical role in the formation of CCM.
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Introduction
Vascular malformations of the cerebrum can lead to devastating life-altering
and/or life-ending events such as seizure and hemorrhagic stroke. These malformations
can be categorized into five groups:
arteriovenous malformations, arteriovenous
fistulas, venous malformations, capillary
telangectasias, and cerebral cavernous
malformations. Cerebral cavernous
malformations (CCM) are a group of
homogenous lesions in the brain, spinal cord
and retina which consist of focal sinusoidal
dilatations of vasculature. CCM are
characterized by a single layer of endothelium,
lacking surrounding smooth muscle, elastin
and central nervous system (CNS)
parenchymal components. Cavernous
malformations manifest most commonly in
the brain and spinal cord, but retinal and
skin malformations are known findings [1],
[2]. CCM exhibit compromised blood brain
barrier due to perturbed endothelial cell to
endothelial cell tight junctions, thus enabling

Figure 1 MRI imaging of CCM. Courtesy of
Murat Gunel MD A. Sagittal & B. Coronal
MR images of a large CCM (arrowhead) that
caused a gross hemorrhage (white arrows) in
a child. C. & D. Axial images of the brain
with the genetic form of CCM reveals
multiple small hypointense lesions due to
hemosiderin (arrows) . E. & F. Axial images
show a typical venous malformation with
multiple enlarged vessels (arrows) seen after
IV administration of contrast material. This
patient previously underwent successful
surgery for removal of and associated CCM.
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red blood cell deposition in adjacent parenchyma. Radiographically, this chronic leakage
can be identified by MRI as a hyper-intense ring of hemosiderin deposition surrounding
the CCM (Figure 1). Autopsy analyses suggest CCM prevalence to be around 0.5%.
CCM make up around 10% of cerebral vascular malformations [3], [4]. Patients
presenting with the clinical manifestations of CCM typically present between the third
and fifth decades of life with seizure, focal neurological deficit or headache [5]. Seizures
represent a common complaint of patients found to have CCM. Studies of patients with
CCM reveal seizure as the presenting symptom in fifty to sixty percent of the study
groups [5], [6]. Symptomatic hemorrhage rates of CCM seem to be around 3% per
patient year with female rates of hemorrhage being higher [7], [6]. CCM are known to
occur sporadically, as well as familial. Clinically, these two mechanisms are indistinct,
but up to 85 percent of familial cases present with multiple lesions, as opposed to only 25
percent of sporadic cases [8], [6]. CCM location correlates to the proportion of neural
tissue through the neuroaxis with approximately eighty percent found supratentorally and
roughly twenty percent of lesions found infratentorally [5], [6].
Significant advances have recently been made in understanding the genetic
causes of CCM’s. Specifically, linkage analysis has led to the identification of three loci
which segregate to familial CCM. These loci have been referred to as CCM1, CCM2 and
CCM3 [9], [19], [31], [32]. The genes which correspond to these loci have been
identified as Krev1/Rap1A Interaction Trapped 1 (KRIT1), MGC4607 (malcavernin) and
Programmed Cell Death 10 gene (PDCD10). Although genetic advances have been
made, the molecular mechanisms leading to CCM formation, as well as, the temporal and
spatial expression pattern and function of KRIT1, MGC4607 and PDCD10 continue to be
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unknown. Recent data have implicated these genes in interactions with the extracellular
environment and apoptosis.
CCM1
Linkage analysis and mutational screening identified a common mutation in Krev
Interaction Trapped 1 (KRIT1) as the genetic source of cavernous malformations in
thirty-one of forty-three Hispanic American kindreds originally from northern Mexico
[9]. Further analysis of this locus, CCM1, revealed a loss of function mutation of the
KRIT1 gene product [10], [9]. Studies using allele specific reverse transcriptase
polymerase chain reaction have revealed germ line, as well as, somatic mutations present
in malformations, but absent in peripheral blood; suggesting a two-hit hypothesis of
CCM formation due to CCM1 [11].
KRIT1 is a small GTP-binding protein originally identified because close
homology with the Ras gene and its ability to revert the Ras transformation phenotype
[12]. The ability to suppress the Ras oncogene has led to the hypothesis that KRIT1 is a
tumor suppressor gene. Analysis of the KRIT1 protein reveals multiple functional
domains. Earlier yeast two hybrid screens have identified Krit1 as a Rap1 binding
partner [12]. Rap1 regulates integrin activation, formation of cell-cell junctions, cell
adhesion [13], [14], [15], [16]. The interaction of Krit1 with Rap1 was confirmed in 2007
by Beraud-Dufour et al. [17]. Using GST pull-down assays, they showed Krit1
preferentially binding GTP-Rap1 through the Krit1 FERM (band four-pointone/ezrin/radixin/moesin) domain. FERM domains are known to allow proteins to
interact with plasma membranes by binding plasma proteins and phosphoinositides [18] .
In fact, Beraud-Dufour et al reported the ability of Krit1 to bind phosphatidyinositol 4,5-
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diphosphate. This study also revealed the interaction of integrin cytoplasmic domain
associated protein (ICAP) with Krit1 through an evolutionarily conserved NPxY
(phosphor-tyrosine binding domain or PTB) domain present near the N-terminus.
Additionally, they provided evidence that the amino and carboxy termini of Krit1 interact
in a folded conformation which can be disrupted and straightened by binding to ICAP
and that ICAP, Rap1 and Krit1 form a ternary complex in vitro. This leads to the
possibility that under certain conditions, Krit1 is transported along microtubules to the
plasma membrane where it binds to GTP-bound Rap1, is opened by ICAP and modulates
beta-integrin signaling.
CCM2
Although CCM1 accounted for the majority of familial cases of CCM amongst
the Hispanic population, familial CCM amongst non-Hispanics was not explained by this
locus. In 1998, Craig et al demonstrated linkage of CCM to two new loci in an outbred
Caucasian population by genome-wide association studies. These loci were located on
the short arm of chromosome 7 (7p15-p13) and the long arm of chromosome 3 (3q25.2q27) [19]. In 2003 the gene which is responsible for CCM2 was revealed. Liquori et al.
[20] sequenced candidate genes found within the boundaries established by Craig et al
1998. This study found eight different mutations in the gene MGC4607 (malcavernin),
each mutation, if translated, leading to a truncated gene product and possibly loss of
function. Interestingly, like ICAP, malcavernin possesses a phosphor-tyrosine binding
domain (PTB) [20].
Concurrent functional studies performed on a newly discovered scaffolding
protein revealed an important role in the p38 signalling cascade. It is well established
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that the p38 MAP kinase pathway is an important mediator in stress induced cell survival
[21], [22]. Uhlik et al (2003) [23] exposed HEK293 cells to a hyperosmotic sorbitol
environment in order to activate the p38 MAP kinase pathway. RNAi experiments
against MEKK3 inhibited sorbitol induced activation of the p38 MAP kinase pathway.
Using MEKK3 as bait in a yeast two-hybrid assay, a small PTB domain containing
protein, similar to known adaptor and scaffold proteins, was identified [23]. RNAi
knockdown of this gene resulted in near-complete inhibition of sorbitol mediated p38
MAP kinase activation. Immunostaining assays demonstrated the recruitment of this
scaffold protein and MEKK3 to dynamic actin under hyperosmotic conditions. The
ability of this scaffold protein under hyperosmotic conditions to bind actin, recruit
MEKK3 to Rac-GTPase containing sites for modulation of the p38 MAP kinase pathway,
led the group to name this protein osmosensing scaffold for MEKK3 (OSM) [23].
Furthermore, CCM2 (OSM) has been directly implicated in CCM1/ICAP/Beta
Integrin signaling. CCM2 can be co-immunoprecipitated with endogenous CCM1 in
mouse embryonic fibroblast cells [24]. Introduction of a mutation into the CCM2 PTB
domain completely prevented co-immunoprecipitation of CCM2 with CCM1.
Specifically, the addition of a mutation, known to be present in a CCM kindred (L198R),
which lies in the C-terminal area of the PTB domain present in CCM2 abolishes CCM2
co-immunoprecipitation with CCM1. Additionally, mutations introduced into a different
NPxY domain on CCM1 known to be important for ICAP binding [25] failed to interfere
with CCM1/CCM2 co-immunoprecipitation. This finding leads to the hypothesis that
CCM1 binds both ICAP and CCM2 through different NPxY/PTB binding interactions
[18] , [24]. The binding of CCM1 partners to different NPxY domains implies that all
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three have the potential to form a complex. As predicted, 293T cells transfected with
MEKK3, CCM1, CCM2 constructs; immunoprecipitated with CCM2 and then
immunoblotted with CCM1 revealed the presence of both CCM1 and MEKK3 [24]. This
provides evidence for a protein complex composed of at least CCM1, CCM2 and
MEKK3.
mRNA expression and Subcellular localization studies have led to the hypothesis
that co-expression of CCM complex constituents can lead to differential sequestration.
Overexpression of a CCM1 construct in 293T cells reveals CCM1 existing in both
cytoplasmic and nuclear compartments. Overexpression of a CCM2 construct in the
same cell line reveals the presence of CCM2 solely in the cytoplasm. Co-expression of
both constructs leads to CCM1 exclusion from the nucleus. These findings support the
conclusion that CCM2 binds to and sequesters CCM1 in the cytoplasm [24], [26].
ICAP and Beta 1-Integrins
ICAP, like Krit1, contains a nuclear localization sequence. Translocation of
ICAP into the nucleus was demonstrated in osteoblasts seeded on beta-integrin substrate
(fibronectin) coated plate. ICAP mediated activation of the c-myc promoter and
subsequent cell proliferation is dependent on this translocation [27]. Additionally,
Overexpression of ICAP causes increased cell motility and adhesion to beta-integrin
substrates [28].
Beta-1-integrins are a set of transmembrane receptors which bind the extracellular
matrix (ECM) and, on the cytoplasmic side, constituents of the cytoskeleton. Beta-1integrins are heterodimeric complexes, composed of one beta-1 subunit and one of a
number of alpha subunits. Mice lacking expression of the beta-1 subunit in radial glia
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exhibit defects in connections of glial foot processes to the basement membrane of the
meninges [29]. Studies using a neural progenitor promoter, Nestin, to drive Cre
recombinase mediated deletion of beta 1-integrin, Belvindra, et al. [30] provided
evidence that neural migration from the ventricular zone to the superficial layers of the
cortex was not dependent on beta 1-integrin expression in neurons. Additionally,
neuronal projections and pyramidal neuron morphology was not perturbed in the Nestin
driven knock-out. In contrast, a mouse completely deficient of beta 1-integrin in the
central nervous system exhibits greatly perturbed development of cortical layers and
pyramidal neuron morphology; leading to the conclusion that beta integrin expression in
radial glia is important for cortical layer and dendritic projection formation and guidance
[30].
With this data from CCM1, CCM2, and ICAP studies, one could imagine a
mechanism which consists of beta-integrin activation (possibly along with a co-stimulant)
leading to CCM1 binding to ICAP and revealing the Talin binding site, allowing Talin to
bind and leading to propagation of the beta-integrin signaling cascade modulating cell
adhesion and migration. Krit1 binding to ICAP, while also bound to malcavernin, brings
malcavernin into close proximity with the plasma membrane where it can bind MEKK3
and modulate the p38 signalling pathway. It would be interesting to know whether (or
when) malcavernin dissociates with the Krit1/ICAP complex, allowing Krit1/ICAP to
translocate to the nucleus and effect cell proliferation, migration and/or adhesion.
Elucidation of this mechanism would fail to address the role of CCM3 in the formation of
cerebral cavernous malformations.
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CCM3
CCM1 and CCM2 mutations account for around sixty percent of familial forms of
the disease [31], [32]. A third locus linked to the familial formation of CCM was
discovered in 2005 [31], [32]. This new locus, CCM3, was found to harbor mutations in
programmed cell death gene 10 (PDCD10). This gene is member of a family of genes
known to be important in regulation of apoptosis. PDCD10 was originally described as
being upregulated in a premyeloid cell line after 8 hours of granulocyte-monocyte colony
stimulating factor (GM-CSF) deprivation and activation of apoptosis [33]. Subsequent
studies have found PDCD10 to be upregulated in skeletal muscle after denervation [34]
and in cultured fibroblasts after exposure to cycloheximide [35]. Unfortunately, increased
expression of the gene in response to apoptotic stimuli does not explain function as cell
survival components could be upregulated, as well as, cell death constituents under
apoptotic conditions. siRNA experiments against PDCD10 in human prostate cancer cell
line (PC-3) cultures led to decreased proliferation, as measured by a tetrazolium salt
assay, over 120 hours. Furthermore, MST4, a Sterile-20 protein kinase, dependent
activation of PC-3 proliferation was inhibited by PDCD10 siRNA [36]. MST4 is a known
modulator of the extracellular-regulated kinase (ERK) pathway [37]. These results
directly implicate PDCD10 in modulation of ERK signaling. It is unclear where
PDCD10 lies in the ERK signaling pathway. In the PC-3 cultures experiments, it seems
that PDCD10 is downstream of MST4. Another possibility is that PDCD10 is part of a
synergistic pathway that, when lost, prohibits the proliferative signals from ERK/MST4
activation. Of interest, integrin signaling has been implicated in the modulation of
mitogen activated protein (MAP) kinase/ERK pathway [38]. This data provides insight
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into the possible connection between beta integrin activation, PDCD10 and ERK
signaling pathway.
CCM3 may bind to CCM2 and its function may be regulated by phosphorylation.
Yeast two-hybrid, in vitro co-immunoprecipitation and GST pull downs have identified
serine/threonine kinase 25 (STK25) and Fas-associated phosphotase (FAP-1) as binding
partners for CCM3. STK25, in vitro, possessed the ability to phosphorylate CCM3.
While FAP-1’s catalytic domain possessed the ability to de-phosphorylate CCM3 [39].
Overexpression of CCM3 in HEK293 cells along with CCM2 and CCM1 resulted in
CCM3 co-immunoprecipitating with CCM2, but not with CCM1 [39]. Additionally,
mutations known to be present in familial CCM have been shown to disrupt the ternary
CCM complex in vitro [40]. These findings support the hypothesis that CCM3 does not
bridge binding of CCM1 to CCM2, but binds directly to CCM2 and not CCM1. The
relationship between CCM1 and CCM3 is dependent on CCM2.

Statement of Purpose
The purpose of our experiments is to further elucidate the function of CCM3. We
will achieve this by using a conditional mouse knock-out of CCM3. Specifically, we
have utilized the bacteriophage derived Cre-recombinase deletion of DNA sequence
flanked by sequence specific loxP sites. We have used cell line specific promoters to
drive Cre-recombination of CCM3-loxP flanked alleles. A mouse harboring a
CCM3floxed allele was generated in the laboratory of Wang Ming PhD (Department of
Pathology, Yale School of Medicine). For the endothelial cell knock-out, the Tie2
promoter was used to drive Cre-recombinase. This mouse was developed in the
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Yanagisawa lab (UT Southwestern). This promoter is known to drive recombination in
endothelial cells present in the embryo, as well as, the yolk sac beginning around e8.5
[41]. Cre-recombination in neural progenitors was driven by the Nestin promoter. This
mouse was obtained through Jackson Laboratories and is known to express Cre at
embryonic day 11. Astrocytes, oligodendrocytes, ependymal cells and a subset of
neurons were targeted for Cre-mediated deletion of CCM3 under the control of the glial
fibrillary acidic protein (GFAP promoter). This mouse was obtained from Jackson
Laboratories and is known to mediate recombination in the above cell lines by e13.5.
We believe knocking-out CCM3 in cells present in the CNS will lead to CCM
formation and possibly an increased number of cells present in the CNS, either by
increased proliferation or decreased apoptosis. We have also used human umbilical
endothelial cells and primary murine astrocytes exposed pro-apoptotic conditions to study
the function of CCM3 in vitro. We believe CCM3 to be important in the apoptotic
pathway. Furthermore, we believe the absence of CCM3 will lead to decreased apoptosis.

Preliminary Data (data performed by others in the lab of Murat Gunel MD)
PDCD10 overexpression promotes cell death
Transfection of HELA cells with the construct pEGFP(C3)-hCCM3 led to an
increase in terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling
(TUNEL) as compared to HELA cells transfected with an empty GFP construct. HELA
cells transfected with a CCM construct displayed morphologic changes consistent with
apoptosis, fragmented nuclei, and exhibited increased expression of caspase-3 (Figures 2
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Figure 2 CCM3 induces apoptosis in HeLa cells. Courtesy of Leiling Chen MD and Murat
Gunel MD. HeLa cells were transfected with GFP-CCM3 or GFP constructs and then serumstarved starting seven hrs after transfection. 50 hrs after transfection, cells were fixed, and nuclei
stained with DAPI (blue). Arrows point to the GFP-CCM3-positive cells (green) with condensed
or fragmented apoptotic nuclei. Scale bar = 20 μm (a). GFP-positive cells were quantified for
apoptosis by scoring apoptotic nuclear morphology as in (a). The percentage of GFP-positive
cells with apoptotic nuclei was represented as mean + SEM from three (n = 5) and four (n = 14)
independent experiments for the 25 and 50 hr timepoints, respectively (left panel). *P < 0.002,
significant difference from GFP-transfected cells; #P < 0.001, significant difference from GFPtransfected cells (by Student’s t-test) (b). Protein expression of GFP and GFP-CCM3 25 hrs after
transfection was confirmed by immunoblotting with anti-GFP. Anti-actin was used as a control
for loading (right panel) (c).
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Figure 3 CCM3 activates caspase-3 in HeLa cells. Courtesy of Leiling Chen MD and Murat Gunel MD. (a)
HeLa cells were transfected with RFP-CCM3 or RFP constructs and then serum-starved starting seven hours
after transfection. 40 hrs after transfection, cells were fixed and immunostained with FITC-anti-active Caspase3 (green), and nuclei were labeled with DAPI (blue). Arrows point to RFP-CCM3-positive cells (red) that are
active Caspase-3 immunoreactive. Arrowheads represent transfected cells that are not active Caspase-3
immunoreactive. Scale bar = 20 μm. (b) RFP-positive cells were assessed for Caspase-3 activation by scoring
active Caspase-3-immunoreactivity as indicated in (a). Histogram represents mean + SEM from three (n = 710) independent experiments for the 25 hr and 40 hr timepoints, respectively. *P < 0.001, significant difference
from RFP-transfected cells; #P < 0.001, significant difference from RFP-transfected cells (by Student’s t-test).
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and 3). This data is consistent with the hypothesis that overexpression of CCM3 leads to
apoptosis.
Introduction of
mutations reported to be
present in kindreds of CCM
(c.283C>T and c.194delA),
which result in a truncated gene
product, into the above
expression vector failed to
increase the amount of cleaved
caspases-3 in HELA
overexpression experiments
(Figure 4).

HUVEC PDCD10 expression
increases under serumdeprivation
Human umbilical vein
endothelial cells cultured in the
absence of fetal bovine serum
(FBS) resulted in increased
expression of cleaved caspase3 after three hours (Figure 5a).

Figure 4 Mutated CCM3 fails to induce apoptosis Courtesy of
Leiling Chen MD and Murat Gunel MD. (a) Transfection with
wildtype CCM3 increases cleaved caspase 3 expression levels,
while transfections with either mutated CCM3 construct has no
effect on cleaved caspase 3 expression. Legend: N=
transfection reagent alone, V= GFP vector alone, CCM3=
transfection with wildtype pEGFP-hCCM3 vector, M1 =
transfection with pEGFP-hCCM3 vector containing the
c.283C>T mutation, M2 = transfection with pEGFP-hCCM3
vector containing the c.194delA mutation. (b) Control western
probed for anti-GFP (Sigma Aldrich, MO ) demonstrates
transfection efficiency. Legend: N= transfection reagent alone,
V= GFP vector alone, CCM3= transfection with wildtype
pEGFP-hCCM3 vector, M1 = transfection with pEGFPhCCM3 vector containing the c.283C>T mutation, M2 =
transfection with pEGFP-hCCM3 vector containing the
c.194delA mutation. (c) Transfections with mutated CCM3
shows reduced cell loss compared to wildtype CCM3. Cell
viability was measured using the 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium (MTT) assay and is graphed as a
percentage of the control culture value (GFP plasmid
transfection group) as quantified by determining the
absorbance of cell cultures at 550 nm. Asterisk denotes P <
0.05 vs. GFP plasmid transfection group.

Interestingly, CCM3 expression preceded the increased expression of cleaved caspases-3.
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Figure 5 Serum-starved endothelial cells result in apoptosis, increased CCM3, activated Caspase 3,
and p38 levels. Courtesy of Leiling Chen MD and Murat Gunel MD. (a) Serum-deprived HUVECs
demonstrate an increase in cleaved caspase 3 levels by hour 3. Graphed densitometric analysis of
cleaved caspase 3 is normalized to GAPDH. (b) CCM3 expression increased upon serumdeprivation starting at approximately 30 minutes, prior to the increase in cleaved caspase-3 levels as
demonstrated by (a). (c) Addition of serum to cell culture rescues CCM3 expression. The x-axis
denotes the addition (+) or absence (-) of different concentrations of FBS (normal=20%,
deprivation=0.2%) over different time points. The graphed densitometric analysis of cleaved
caspase 3 is normalized to GAPDH as demonstrated by the western blot above. (d) Cell cultures
were incubated with various concentrations of Actinomycin D (x-axis, top), a transcription inhibitor
at time=0 and =1 hour (x-axis, bottom). Actinomycin D treatment inhibits CCM3 expression
confirming that serum starvation causes an increase in CCM3 transcription. (e) Serum deprivation
results in an increase in activated (p-) p38 prior to activated caspase 3 activation as demonstrated by
(a). Levels of p-p38 increase dramatically upon serum starvation at 6 minutes, followed by a second
peak beginning at 3 hours.

Increased CCM3 expression was noticeable as soon as thirty minutes after withdrawal of
FBS (Figure 5b). The observed increase in CCM3 expression was reversible after
reintroduction of FBS into the cell culture medium (Figure 5c). To confirm the effect of
serum deprivation on CCM3 transcription, cultures were exposed to the transcription
inhibitor actinomycin D. Actinomycin D inhibited the transcription, and therefore
translation, of CCM3 (Figure 5d).
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Given the known effect of CCM1/CCM2 signaling on the MAP kinase/p38
pathway, our group investigated how serum deprivation effected p38 activation. Serum
deprivation increased the abundance of phosphorylated p38. The increase of
phosphorylated p38 preceded the increase in CCM3 expression and also cleaved caspase3 (Figure 5e).
PDCD10 siRNA
decreases cell death
Under the FBS
deprivation conditions
described above,
HUVECs were exposed
to PDCD10 siRNA.
Inhibition of PDCD10
led to decreased TUNEL
positivity which reached
statistical significance at
3 hours (Figure 6a).
PDCD10 siRNA also led to
muting of the increased level

Figure 6 siRNA inhibition of CCM3/PDCD10 expression results in
decreased cell death, p38, and activated Caspase-3 expression.
Courtesy of Leiling Chen MD and Murat Gunel MD. (a) HUVECs
treated with PDCD10 siRNA demonstrate decreased p38 expression
levels compared to controls. (b) Serum-deprived HUVECs treated
with PDCD10 siRNA show decreased apoptosis. (c) Serum-starved
HUVECs show decreased activated caspase 3 levels after treatment
with PDCD10 siRNA.

of cleaved caspase-3 seen
under serum deprivation (Figure 6b). Additionally, PDCD10 siRNA conditions led to an
attenuated increase in p38 expression (Figure 6c). This data further implicates CCM3 in
the CCM1/CCM2 signaling pathway.
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The above in vitro experiments provide strong evidence of CCM3’s role in
apoptosis. Overexpression of CCM3 led to increased morphological changes consistent
with apoptosis, as well as, increased expression of the pro-apoptotic gene caspases-3.
Serum deprivation experiments led to increased expression of CCM3, p38 and cleaved
caspase-3. PDCD10 siRNA experiments led to an attenuation of the pro-apoptotic
response. These results suggest that PDCD10 acts as a regulator of apoptosis.
Specifically, PDCD10 expression promotes apoptosis. PDCD10 may act as in a tumorsuppressor like manner. Loss of PDCD10 function may lead to decreased apoptosis in
vivo.
GFAP-Cre;CCM3lox/lox mice exhibit multiple developmental abnormalities
Mutant (GFAP-Cre;CCM3lox/lox) mice are born according to the expected
Mendelian ratio, although many fail to survive past weaning. Mutant mice weigh less
and possess smaller bodies than littermate control animals, but have larger brains (Table
1). Mutant mice display severe ataxia, often moving in a circle.
Expression of CCM3 mRNA, as measured by in situ hybridization, is reduced in
the mutant CNS. Expression was not completely ablated and is expected to be
unperturbed in the endothelium and most neurons (Figure 7).

Table 1 Analysis of GFAP-Cre;Ccm3lox/lox animals reveals small body size but enlarged brain. Brain
weight when corrected for body weight is 1.5-2.7 times that of control littermates. Courtesy of
Angeliki Louvi PhD and Murat Gunel MD
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Expression of GFAP is

P6 control

P6 experimental

mutant CNS (Figure 8). The

CCM2

increased throughout the

increase in GFAP expression

proliferation of GFAP

CCM3

could be a product of increased

expressing cells or a decrease
in apoptosis present in the early
development of the CNS. The
large axon tracts of the corpus
callosum are substantially thinner

Figure 7 Ccm3 mRNA (lower panel), is significantly
downregulated in the brains of GFAP-Cre; Ccm3lox/lox
animals (lower right). As a control, we evaluated
Ccm2 mRNA in both experimental and control
animals as well and found it be unaltered (upper
panels). Courtesy of Angeliki Louvi PhD and Murat
Gunel MD

in the mutant brain. This result is evident upon sectioning, as well as, MRI and
represents either a perturbation of myelination or a perturbation of axonal migration
(Figures 8 and 9). Enlarged CNS vasculature was a finding which was observable by
MRI and sectioning (Figures 9 and
10). Cerebrovascular capillaries,
identified through in situ
hybridization, were disorganized
compared to control CNS, often
lacking a vertical orientation (Figure
Figure 8 GFAP staining of GFAPCre;PDCD10-/mouse (right panel) at P21 as compared to controls (left
panel) reveal increased glial cell numbers and brain
mass in the experimental animals. Courtesy of Angeliki
Louvi PhD and Murat Gunel MD

11). Analysis of the cerebellum
through immunohistochemistry with
antibodies against neurofilament
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revealed a lack of Purkinje cell
monolayers, possibly
accounting for the problems
with gait observed in mutant
mice (Figure 12).
Most GFAPCre;CCM3lox/lox mice do not
survive past weaning. Analysis
Figure 9 MRI imaging of a live 8 month GFAP-Cre;Ccm3lox/lox
mice reveals enlarged vessels (red arrows) in A. and B.
Interestingly, fractional anisotrophy detects thinner while
matter in corpus callosum in experimental animal (red arrow)
compared to a littermate D. Please note the larger brain size of
the mutant in C. as compared to D. Courtesy of Murat Gunel
MD

of five mutants which survived
past weaning revealed a
persistent weight discrepancy
between mutant and control,
with the mutants weighing on
average 80% that of the control
mice. One adult mutant
presented with two superficial
vascular malformations one
near the olfactory bulb and the
other near the pons (Figure 13).

Figure 10 Histological examination of the brain of the
GFAP-Cre;Ccm3lox/lox mutants reveal enlarged vessels (red
arrows). Courtesy of Angeliki Louvi PhD and Murat Gunel
MD

These malformations are very
similar to lesions present in

patients with CCM. MRI performed on two additional adult mutants revealed the
presence of dilated vasculature, a finding common in human CCM (Figure 9).
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Figure 11 The organization of the cerebrovascular capillaries appear less orderly in the experimental animals (right
panel) at P6 compared to controls (left panel) based on Col4a1 in-situ hybridization. Courtesy of Angeliki Louvi
PhD and Murat Gunel MD

Figure 12 Purkinje cells are disorganized and appeared supernumerous in the cerebellum of the P16 experimental
animals (right panel) as compared to controls (left panel) and as shown by axonal staining with neurofilament
fluorescence. Courtesy of Angeliki Louvi PhD and Murat Gunel MD

Deletion of CCM3 effects proliferation and apoptosis in primary astrocyte culture
Astrocytes were isolated from GFAP-Cre;CCM3lox/lox and GFAP-Cre;CCM3lox/+
mice as described below. Cells were plated at equal concentrations and allowed to grow
in culture for 1, 2, and 3 days. Proliferation was measured by 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT, a tetrazolium salt) assay on each day.
Reduction of the tetrazolium salt in the mitochondria can be measured using a
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Figure 13 CCM lesions in a 7 month old
GFAPCre;PDCD10-/- mouse. Multiple CCM
lesions, two within the olfactory bulb and a large
lesion on the cerebellum (red circles) are seen
(upper left panel). Higher magnification (lower
left panel), reveals enlarged vessel (arrow) around
the CCM lesion which is a common finding in
human CCM disease (associated venous
malformation). Right upper panel shows an
enlarged view of the cerebellar lesion with
characteristic CCM caverns. Courtesy of Angeliki
Louvi PhD and Murat Gunel MD

spectrophotometer and correlates to the number of viable cells in culture. GFAPCre;CCM3lox/lox cultures displayed a growth advantage at day 1, which persisted through
day 3 (Figure 14).
The increased MTT signal in the GFAP-Cre;CCM3lox/lox cultures could be
explained by decreased apoptosis, increased proliferation or both. To further elucidate
life cycle changes, cultures were analyzed by immunohistochemistry using antibodies
against Ki67, a known marker of proliferation. GFAP-Cre;CCM3lox/lox cultures exhibited
increased proliferation within 24 hours as compared to GFAP-Cre;CCM3lox/+ cultures
(Figure 15). This result was confirmed by BrdU assays (Figure 16).
Next, our group exposed primary astrocytes to cycloheximide, a known inducer of
apoptosis. GFAP-Cre;CCM3lox/lox cultures did not undergo apoptosis as GFAP-
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Cre;CCM3lox/+ cultures, as
measured by TUNEL (Figure 17).
Additionally, cycloheximide
induced an increase of cleaved
caspase-3 in the GFAPCre;CCM3lox/+ culture. This effect
was attenuated in the GFAPCre;CCM3lox/lox culture (Figure
Figure 14 CCM3 deletion induced increase in
proliferation was evaluated with MTT assay.
Astrocytes were seeded at 1 × 102/cm2 on poly-Lornithine coated 96 well plates. The cells were
allowed to attach overnight. At different time point
(day 1, 3, 5 ), add 20 ul of MTT solution (5mg/ml) to
each well containing cells. The absorbance was read at
550nm. Courtesy of Leiling Chen MD and Murat
Gunel MD

18).
Deletion of CCM3 effects integrin
dependent cell function
Beta-1 integrin’s role in
cell adhesion and migration is well

established [42], [43] [44], [45]. Cell migration was tested by allowing cultures to grow
to confluence then scratching the culture dish with a pipette tip. Migration through the
cell free zone was stunted in the GFAP-Cre;CCM3lox/lox cultures and continued to trail the
GFAP-Cre;CCM3lox/+ cultures through 48 hours (Figure 19).
Cell adhesion was tested using three different substrates (Figure 20). Neither
culture adhered well to vitronectin. Both GFAP-Cre;CCM3lox/lox and GFAPCre;CCM3lox/+ cultures exhibited a higher affinity to the beta-1 integrin substrates,
fibronectin and laminin. Although the GFAP-Cre;CCM3lox/lox cells tended not adhere as
well to beta-1 integrin substrates, the difference is insignificant. The question remains of
how the GFAP-Cre;CCM3lox/lox cultures would compare to a wild-type control.
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Figure 15 Alternatively, CCM3 deletion induced
increase in proliferation was evaluated with ki67
immunohistochemistry staining: Astrocytes were
seeded on poly-L-ornithine coated 4 well culture
slides. At different time point, the cells were fixed in
4%PFA, and the percentage of positive ki67 per high
field (x40) was count. The photo-imagine show the
representative imagine for the ki67 immunostaining at
24 hours culture (x20). The positive ki67 is green and
nuclear staining, the blue is DAPI counter staining. A.
control astrocyte; B Mutant astrocyte; C. quantization
of positive ki67 percentage. Courtesy of Leiling Chen
MD and Murat Gunel MD

Figure 16 Furthermore, CCM3 deletion
induced increase in proliferation was
evaluated with BrdU incorporation assay:
Astrocytes were seeded on poly-Lornithine coated 4 well culture slides, and
incubated with 10um BrdU. At different
time point, the cells were fixed in 4%PFA,
and the percentage of positive BrdU per
high field (x40) was count. The photoimagine show the representative imagine
for the BrdU immunostaining at 24 hours
culture (x20). The positive BrdU is green
and nuclear staining, the blue is DAPI
counter staining. A comes from control
(GFAP Cre;lox/+); B comes from mutant
(GFAP Cre; lox/lox). Courtesy of Leiling
Chen MD and Murat Gunel MD
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Methods (performed by
author)
Mouse Colony.
Experiments were carried out
in accordance with protocols
approved by the Institutional
Animal Care and Use
Committee at Yale
Figure 18 CCM3 deletion in astrocyte results in resistance of
cycloheximide induced apoptosis: . Astrocytes were seeded at
2 × 105 on poly-L-ornithine coated 10cm plates, and incubated 48
hours, then 20ug/ml cycloheximide was added into medium. At
different time point, cells were lysed, and followed with western
blotting. Courtesy of Leiling Chen MD and Murat Gunel MD

University School of
Medicine. Mouse colonies
were maintained at Yale

University, in compliance with National Institutes of Health guidelines and with the
approval of Yale University Institutional Animal Care and Use Committee. To generate
experimental animals, males with the genotype of Promoter-Cre;CCM3lox/+ were mated
with females lacking the Cre transgene and possessing a CCM3lox/lox genotype. For timed
pregnancies, midday of the day of vaginal plug discovery was considered embryonic (e)
day 0.5. Mice at embryonic and postnatal stages through adulthood were used. For
embryonic stages, pregnant females were anesthetized and pups at appropriate stages
were dissected from the uterus. Embryonic brains/neural tubes were dissected and fixed
by immersion in 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS)
overnight. Mouse pups [postnatal (P) day 0 through P2] were anesthetized on ice, then
the brains were removed and fixed in 4% PFA overnight. At all other stages, mice were
anesthetized and intracardially perfused with 4% PFA.
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DNA Preparation from Mouse Tissue. Tissue
was collected from the mouse for genotyping.
For embryonic mouse stages the yolk sac was
taken and for later stages (postnatal day 0 or
older) a small portion of tail was taken. The
tissue was combined with 90 μl of sterile water
and incubated at 95°C for 10 minutes. The
samples were briefly spun down and brought
down to room temperature (2-3 minutes). 10
Figure 19 : Deletion of CCM3 results in
Deletion decreased migration of astryocte.
Astrocytes are plated in tissue culture
dishes (10mg/ml poly-L-ornithine coated),
and after 24 h of incubation, the confluent
monolayer of cells was scratched in a
standardized manner with a plastic tip to
create a cell-free zone in each well, 2 mm
in width. The medium was aspirated and
replaced with DMEM/F12 plus 10% FBS.
At desired time point, the cells were fixed
in 4%PFA, and stained using 0.1%crystal
violet. In vitro re-epithelialization was
documented by photography. Courtesy of
Leiling Chen MD and Murat Gunel MD

μl of proteinase K (at 2 μg per μl
concentration) was added and mixed well. The
samples were then incubated at 55°C
overnight and then 95°C for 10 minutes to
inactivate the proteinase K. After
centrifugation the resulting supernatant was
used for PCR analysis.

PCR. PCR was performed to genotype the transgenetic mouse lines used in this study.
The standard reaction contained 10 μl 2x FailSafeTM Buffer Premix F (Epicentre,
Madison, WI), 0.3 μl of 10 μmol of each primer, 0.5 μl of DNA, and 0.2 μl of Taq DNA
polymerase isolated from an E. coli strain that carries the DNA polymerase gene from T.
aquaticus. The amplification protocol was comprised of a denaturation step at 95°C for 4
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min, followed by 35
cycles of a 95°C
denaturation step for 30
sec, an annealing step at
55°C for 30 sec, and a 45
sec extension step at
Figure 20 CCM3 deletion results in no change in adhesion of astrocye
to extracellular matrix. Murine lamnin-1, bovine fibronectin, and
bovine vitronectin will be obtained from Sigma. 10ug/ml of ECM
solution is added on Petri dish 2 hous at 37ºC. Before addition of
cells, all substractes were blocked with heat-inactivated bovine serum
albumin to prevent non specific binding the substrates. After washed
with PBS, the cells (2x103) added for 30 minutes. The adhesion assay
is stopped by adding DMEM/F12 plus 10% FBS to the Petri dish and
washed off loosely attached cells. The attached cells are then fixed
with 4% paraformaldehyde in PBS for 20 minutes. Adhesion was
quantified counting all attached cells under phase microscopy.
Courtesy of Leiling Chen MD and Murat Gunel MD

72°C. The reaction was
completed with a 10 min
extension step at 72°C.
The primers used to for
genotyping were as
follows: Cre primer 1,

CCGGGCTGCCACGACCAA; Cre primer 2, GCGCGGCAACACCATTTTT, CCM3
primer 1, CTCAGTGTAGTCATGAAAAGAGT; CCM3 primer 2,
CCAGCATCCTTTGCCTCTCC. The Cre primer set generated a 500 base pair product.
The CCM3 primers resulted in a 150 base pair product for the knock-out genotype
compared to a 103 base pair product for the wild-type genotype. PCR products were
analyzed using gel electrophoresis.

Riboprobe synthesis for in situ hybridization. Templates for riboprobe synthesis were
derived from cloned mouse cDNA sequences of the corresponding genes: T-box brain
gene 1 (TBR1), Chick ovalbumin upstream transcription factor I (COUP-TFI), Calbindin
(CALB), Pou Domain, class 3, transcription factor 1 (SCIP), Ephrin A5, Notch,
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Retinoid-related orphan receptor alpha (RORα), β-tublin. The constructs were
previously made and consisted of the cDNA inserted 3’ to 5’ in respect to a T7 promoter
in a plasmid DNA backbone. This design allows for an anti-sense RNA transcript to be
synthesized utilizing T7 RNA polymerase and digoxigenin-11-UTP. Before RNA
synthesis, plasmids were first linearized with a restriction enzyme digest. After digestion,
the reaction was treated with 0.005% sodium dodecyl sulfate (SDS) and proteinase K
(final concentration of 0.7 mg/ml) for 15 minutes at 37°C. The DNA templates were then
purified using a phenol/chloroform/isoamyl alcohol extraction. Briefly, a
phenol/chloroform/isoamyl solution (25 parts phenol to 24 parts chloroform to 1 part
isoamyl alcohol) was added at an equal volume to the DNA sample. After inverting
several times, the samples were spun down at 14,000 rpm for 5 minutes and the aqueous
phase (top layer) was transferred to a new tube. An equal volume of chloroform/isoamyl
alcohol (24 parts chloroform to 1 part isoamyl alcohol) was then added, mixed well,
centrifuged down at 14,000 rpm for 5 minutes, and the aqueous layer was removed again.
This last step was repeated once more. An ethanol precipitation of the DNA was then
performed by adding 2.1 times the volume of 100% ethanol and 0.1 times the volume of
3 M sodium acetate. The DNA was incubated on ice for 15 minutes and spun down at
14,000 rpm for 15 minutes at 4°C. The supernatant was discarded and the pellet was
washed with 70% ethanol and centrifuged at 14,000 rpm for 5 minutes. The pellet was
allowed to dry and resuspended in 20 μl of DEPC-treated H20. This linearized and
purified DNA was then used as the template DNA for riboprobe transcription. The
transcription reaction consisted of 1 μg of DNA, 2 μl of 10x transcription buffer, 2 μl of
nucleotide mixture (containing digoxigenin-11-UTP), 1 μl RNase Inhibitor, 1 μl of 100
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mM DTT, and 2 μl T7 RNA polymerase. The reaction was incubated at 37°C for 2 hours.
2 μl of DNase was then added and incubated for 15 minutes at 37°C. The RNA was
precipitated by adding 100 μl of DEPC-treated H20, 10 μl of lithium chloride and 300 μl
of 100% ethanol and incubated on ice for 15 minutes. The RNA was pelleted by spinning
at 14,000 rpm for 15 minutes at 4°C and washed once with 70% ethanol. After drying the
pellet, the riboprobe was resuspended in 100 μl of DEPC-treated H20 and checked for
quality on an agarose gel.

In situ hybridization. Mouse brains were post-fixed overnight in 30% sucrose/4% PFA
and sectioned in the coronal plane on a Leica sledge cryomicrotome at 36 μm (Leica
Microsystems, Germany). Sections were mounted on slides and allowed to dry overnight
before further processing. For the in situ hybridization all incubation and wash steps were
performed on a rocker when possible in RNase-free conditions. The slides were first
treated with 4% PFA for 15 minutes and wash 3 times for 5 minutes each in DEPC-PBS.
For mouse stages P0 through P20 the slides were incubated in detergent solution
(consisting of) for two 15 minute intervals. For older stages, 30 minute incubation
periods were used and no detergent treatment was used for embryonic tissue sections.
After detergent treatment, the slides were washed once in DEPC-PBS and then incubated
with proteinase K solution (at a concentration of 1.02 μg/ml) for 30 minutes at 37°C.
Slides were fixed again in 4% PFA for 15 minutes and then washed three times 5 minutes
in DEPC-PBS. Then the slides were pre-incubated in hybridization solution (consisting
of) at 70°C for an hour. 70 μl of the prepared riboprobe (see above) was added to 14 ml
of hybridization and mixed. Slides were incubated in the riboprobe solution overnight at
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70°C. The following day slides were washed in a stringent wash (containing
formaldehyde) three times for 45 minutes each at 70°C. Then three washes with Trisbuffered saline containing 0.1% Tween-20 (TBST) were performed. The slides were
placed in blocking step in 10% lamb serum in TBST for 60 minutes prior to incubation
with an alkaline phosphotase conjugated anti-DIG antibody (at a 1:5000 concentration in
1% lamb serum TBST) for 2 hours at room temperature. Three washes in TBST for 15
minutes were done before developing with 5-Bromo-4-Chloro-3'-Indolyphosphate pToluidine Salt (BCIP) and Nitro-Blue Tetrazolium Chloride (NBT). Development time
differed depending on the riboprobe ranging from overnight to 2 days. Afterwards the
slides were dehydrated in a series of ethanol steps, cleared with Histoclear (a xylene
substitute) and cover-slipped. Sections were analyzed using a Zeiss Stemi dissecting
microscope or a Zeiss AxioImager (Zeiss, Oberkochen, Germany) fitted with an
AxioCam Mrc5 digital camera. Images were captured using AxioVision AC software
(Zeiss) and assembled using Adobe Photoshop.

Nissl Stain. Mouse brains were perfused, prepared and sectioned as described above.
36μm sections on Fisherbrand Superfrost microscope slides were dried at room
temperature (RT) overnight. Samples were placed in 4% PFA for 15 minutes on a rocker
at RT. Next, samples were rinsed twice in PBS for 5 minutes each wash at RT. Samples
were then soaked in distilled water (DW) for 1 minute. Samples were then exposed to an
ethanol gradient for one minute in each: 70, 80, 90, 95, 100, 100%. Samples placed in
xylene for 1 minute and then another xylene bath for 30 minutes. Samples were then
transferred back to the first xylene bath for one minute and then down the ethanol
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gradient, in each bath for one minute (100, 100, 95, 90, 80, 75). Samples were placed in
DW for one minute. Next samples were incubated at 42o C for 5 minutes in 0.1% Cresyl
Violet in DW (previously filtered through 3mm filter paper). Samples were then washed
in DW to remove excess stain. Samples then were exposed to acid ethanol (100%
ethanol, trace acetic acid) for 5-10 minutes until contrast was appropriate. Samples were
transferred to an ethanol gradient for one minute in each concentration (, 80, 90, 95, 100,
100%). Samples were then bathed in Histoclear 3 times for 1 minute each. Slides were
then coverslipped with Eukitt. Sections were analyzed using a Zeiss Stemi dissecting
microscope or a Zeiss AxioImager (Zeiss, Oberkochen, Germany) fitted with an
AxioCam Mrc5 digital camera. Images were captured using AxioVision AC software
(Zeiss) and assembled using Adobe Photoshop.

BrdU Assay. Pregnant mice were subjected to intraperitoneal injections of 5-bromo-2deoxyuridine (BrdU) 20μg/g at appropriate embryonic time points measured by date of
seminal plugging. For short course experiments, pregnant mice were sacrificed 3 hours
after injection of BrdU. Embryos were dissected and fixed in 4% PFA for 2 hours. Long
course experiments consisted of post-natal time points (P0 or P2). At these time points,
mouse brains were perfused, prepared and sectioned as described above. Sections were
mounted on slides and allowed to dry overnight before further processing. All incubation
and wash steps were performed on a rocker when possible. The slides were first treated
with 4% PFA for 15 minutes and wash 3 times for 5 minutes each in DEPC-PBS. For
mouse stages P0 through P20 the slides were incubated in detergent solution (consisting
of) for two 15 minute intervals. For older stages, 30 minute incubation periods were used
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and no detergent treatment was used for embryonic tissue sections. After detergent
treatment, the slides were washed once in DEPC-PBS and then incubated with proteinase
K solution (at a concentration of 1.02 μg/ml) for 30 minutes at 37°C. Slides were fixed
again in 4% PFA for 15 minutes and then washed three times 5 minutes in DEPC-PBS.
Then the slides were pre-incubated in in-situ hybridization solution (without riboprobe) at
70°C overnight. Slides were washed in Solution X twice for 20 minutes each at 70°C.
Two TBST washes were performed for 10 minutes each at RT. Slides were bathed in 2N
HCL for 30 minutes at RT. Four washes in 100mM Tris-HCl (pH 8.5) for 5 minutes each
were performed. Samples were then washed in TBST, three times, for 5 minutes each.
Next slides were blocked in 10% lamb serum in TBST for 60 minutes at 4°C. Anti-BrdU
antibodies were added to slides and placed at 4oC overnight. Three washes in TBST for
15 minutes were done before incubating with anti-fluorophore antibody in 1% lamb
serum overnight at 4oC. Slides were washed three times in TBST then developed with 5Bromo-4-Chloro-3'-Indolyphosphate p-Toluidine Salt (BCIP) and Nitro-Blue
Tetrazolium Chloride (NBT). Afterwards the slides were dehydrated in a series of
ethanol steps, cleared with Histoclear (a xylene substitute) and cover-slipped. Sections
were analyzed using a Zeiss Stemi dissecting microscope or a Zeiss AxioImager (Zeiss,
Oberkochen, Germany) fitted with an AxioCam Mrc5 digital camera. Images were
captured using AxioVision AC software (Zeiss) and cells counted using ImageJ v1.38
software (NIH). Statistical analysis was not performed on these pilot experiments, but
will be performed in the future.
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Astrocyte Cultures. Primary astrocytes for FACS analysis were isolated and cultured
from early post-natal mice (P0-P2) by Leiling Chen MD using an established protocol
[46]. For the apoptosis experiments, astrocytes were exposed to media containing 20
mg/ml cycloheximide. Cells were harvested after 3 hours for FACS analysis.

HUVEC Cultures. Human umbilical vein endothelial cells (HUVECs) were obtained
from the Vascular Biology and Transplantation Program at Yale University School of
Medicine (New Haven, CT). HUVECs were grown on 0.1% gelatin coated 6-well plates
using 20% fetal bovine serum (FBS), 1% endothelial cell growth supplement (ECGS) in
M199. Media was changed every third day. Cells were used in experiments between
passages 3-6. For experimental conditions, HUVECs were grown to confluence (~2 days
in culture). Next, fresh media was supplemented with antibody to β1-integrin (P4C10 or
TS2/16) or mouse IgG. Cells were harvested for western blotting after 72 hours of
incubation.

Western Protocol. Cells were harvested and total protein from the cells was extracted in
a lysis buffer (150mM NaCl, 1%Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS,
50mM Tris-HCl pH 8.0 and protease inhibitors, 1mM Na3V04, 10mg/ml leupeptin,
10mg/ml aprotinin and 4mM PMSF). Cell lysate was centrifuged, supernatant collected
and stored at -80oC. Equal amounts of protein (approximately 50 µg/lane) were loaded
into a 4-15% gradient polyacrylamide gel, separated by electrophoresis (Bio-Rad
Laboratories, CA) and transferred onto a PVDF membrane (Bio-Rad Laboratories, CA).
The membranes were incubated with primary antibody (caspase 3 antibody or anti-β-
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actin [Santa Cruz, CA]) overnight at 4oC. HRP conjugated secondary antibodies were
used for visualization.

Annexin/PI Fluorescence Activated Cell Sorting. Primary astrocyte cultures (GFAPCre;CCM3lox/lox and GFAP-Cre;CCM3lox/+) were trypsinized and washed with PBS. Cells
were resuspended in 100μl of Annexin V Incubation Reagent (R and D Systems,
Minneapolis, MN) per 106 cells for 15 minutes in the dark. Cells were acquired using a
FACSCalibur flow cytometer (BD Biosciences). Analysis was performed using WinMDI
v2.9. The astrocyte population was identified by forward and side-scatter properties. A
threshold for annexin staining was set using the FITC channel by observing unstained
(control) populations. Likewise, propidium iodide fluorescence was measured by using
the PE channel in unstained (control) populations. From this data, quadrants were set and
data acquired. Statistical analysis was not performed on these pilot experiments, but will
be performed in the future.

Results
Tie2cre
Cre recombinase mediated recombination of CCM3 loxP sites, under the control
of the endothelial cell specific promoter Tie2 failed to produce viable offspring which
were homozygous for the CCM3 lox allele (Tie2-Cre;CCM3lox/lox). Heterozygous pups,
Tie2-Cre;CCM3lox/+, were found in an expected Mendalian manner. Gestational
sacrifices revealed viable Tie2-Cre;CCM3lox/lox embryos at e9.5. Analysis of intact yolk
sacs revealed a difference in vascular development between mutants and controls (Figure
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21 A and B). This phenotype was also present at e10.5 (Figure 21 E and F). At e9.5 and
e10.5, mutants were readily distinguishable from control littermates, being smaller in size
Figure 21 e9,5 and E10.5
Tie2-Cre;Ccm3lox/lox exhibit
yolk sac and pericardial
developmental
abnormalities. E9.5 and
E10.5 control yolk sacs
display
age
appropriate
vascular tree development (a
and e). E9.5 and E10.5 Tie2
KO yolk sacs retain a
primitive yolk sac consisting
of islands of blood, lacking a
vascular tree (b and f). E9.5
and E10.5 embryos exhibit a
dilated pericardial region
compared to controls (C, D,
G and H).

and also containing a dilated cardiac region (Figure 21 C, D, G and H). A beating heart
was present at e9.5, but was not observed at e10.5. No change in phenotype or
developmental stage was apparent between e9.5 and e10.5 mutants.
Whole mount anti-PECAM staining revealed abnormal formation of the lower
branchial arches (data not shown). India ink injected into the ventricle of e9.5 mutants
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Figure 22 Tie2-Cre;Ccm3lox/lox embryos fail to develop normal vascular connections. Tie2Cre;Ccm3lox/lox E9.5 embryos (b) injected with India ink into the primitive ventricle did not diffuse out
of the heart, through the branchial arteries and down the dorsal aorta as littermate controls (a).

failed to travel through the distal caudal aorta (Figure 22). India ink mostly accumulated
in the pericardial region in Tie2-Cre;CCM3lox/lox embryos. Some ink traveled into
branchial arteries 2 and 3, although these arteries appeared constricted compared to
control embryos. Dorsal aortae proximal to the heart were not easily identified in
hematoxilin and eosin stained sections of e9.5 mutant embryos, but were readily
identified in control embryos (Figure 23 A and C). Immunoflourescence of PECAM
revealed the presence of endothelial cells, although the lumen lacked normal patency
(Figure 23 B and D).
GFAPcre
Cre mediated recombination of CCM3 lox sites under the control of the GFAP
promoter produced viable mutant mice at a frequency lower than the expected Mendelian
ratio. GFAP-Cre;CCM3lox/lox pups can be phenotypically identified by gait abnormalities,
small body habitus and a larger, rounder cranium (data not shown). Repeat polymerase
chain reaction on phenotypically similar littermates revealed that there are a few GFAPCre;CCM3lox/+ mice heterozygous for the lox allele which display a dysmorphic

39

Figure 23 Tie2-Cre;Ccm3lox/lox embryos display abnormal dorsal aortae. H and E
staining of E9.5 cross sections revealed an apparent lack of doral aortae in the Tie2Cre;Ccm3lox/lox embryos (a and c). Subsequent immunohistochemistry with PECAM
revealed the presence of endothelium and dorsal aorta with a significantly smaller lumen
in the Tie2-Cre;Ccm3lox/lox embryos (b and d). NT = Neural Tube, DA = Dorsal Aorta

appearance, but not as severe as mutants. These littermates do not seem to have the gait
abnormalities seen in the mutants.
Nissl staining of coronal sections revealed generalized disorganization of the
cortical layers, hippocampus (including a smaller dentate gyrus) and cerebellum (Figure
24). In situ hybridization assaying known markers of cortical layering suggest a
perturbation in neuron migration from the deeper layers to the more superficial layers of
the cortex (Figure 25).
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Figure 24 Nissl staining reveals abnormal cytoarchitecture. Adult GFAP-Cre;Ccm3lox/lox (b)
exhibit generalized disorganization of cortical layers compared to control mice (a). Development
of the hippocampus is perturbed; GFAP-Cre;Ccm3lox/lox mice displayed abnormal layering and a
smaller dentate gyrus.

BrdU assays on cortical sections of embryonic day 14.5 embryos performed 3hr
after injection of BrdU revealed decreased BrdU staining in cortical areas, excluding the
ventricular layer (Figure 26). At e16.5, GFAP-Cre;CCM3lox/lox mice exhibited less BrdU
uptake in layers of the somatosensory cortex above the ventricular zone and the basal
ganglia (Figure 27). This trend was not observed in the visual cortex.
GFAP-Cre;CCM3lox/lox Astrocyte Culture
Astrocyte cultures isolated from postnatal day 1 GFAP-Cre;CCM3lox/lox mice and
GFAP-Cre;CCM3lox/+ mice exposed to cycloheximide and assayed by annexin-PI
fluorescence activated cell sorting revealed a trend towards resistance to apoptosis in the
mutant cultures (Figure 28).
Activation of β-1 integrin increase caspase-3 expression
The ability of antibodies to activate and block beta-1 integrin function was tested
in our HUVEC culture conditions. Interestingly, P4C10, an antibody known to block
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beta-1 integrin signaling [47], [37] decreased expression of caspase-3, as compared to
control cultures. Conversely, TS2/16, an antibody known to promote beta-1 integrin
signaling [48], slightly increased expression of caspase-3 (Figure 29).
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Figure 25 In situ hybridization on GFAPCre;Ccm3lox/lox
sections
exhibit
abnormal
development of cerebral cortical and cerebellar
layers. Tbr1, SCIP, ephrinA5, CoupTF1 anti-sense
probes were used to observe the development of
cortical layers. Ror-α was used to analyze the
cerebellum. GFAP-Cre;Ccm3lox/lox (right column) do
not develop normal cortical layers as seen in control
mice (left column).
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Figure 26 Three hour BrdU incorporation differs between GFAPCre;Ccm3lox/lox and GFAP-Cre;Ccm3lox/lox mice. GFAP-Cre;Ccm3lox/lox
cortical sections (-/-, C and D) exhibit less BrdU incorporation compared to
GFAP-Cre;Ccm3lox/l+ cortical sections (+/-, A and B). Quantification was
achieved with Image J software (E).
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Figure 27 GFAP-Cre;Ccm3lox/lox and GFAP-Cre;Ccm3lox/+
mice differ in the number of dividing cells present in the
somatosensory cortex and basal ganglia. BrdU injections were
performed at E16.5. Mice were sacrificed and assayed for BrdU
incorporation at P2. GFAP-Cre;Ccm3lox/lox brains displayed less
BrdU incorporation in the somatosensory cortex than GFAPCre;Ccm3lox/+ brains (A and B). This finding was not obvious in
the visual cortex (C and D). GFAP-Cre;Ccm3lox/lox also exhibited
less BrdU incorporation in the basal ganglia (E and F). BrdU
positive cells were quantified using Image J software (G). GFAP
Het = GFAP-Cre;Ccm3lox/+ , GFAP KO = GFAP-Cre;Ccm3lox/lox ,
Ssc = somatosensory cortex, Vc = visual cortex, BG = basal
ganglia, +/- = GFAP-Cre;Ccm3lox/+ , -/- = GFAP-Cre;Ccm3lox/lox
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Discussion
Mice deficient in endothelial cell
CCM3 are similar to CCM1
knockouts
Endothelial cell specific
knockouts of CCM3
developmentally arrested around
e9.5, one day after activation of the
Tie2 promoter. Phenotypically,
these mice resembled CCM1
homozygous knockout mice.
Specifically, both CCM1
homozygous knock-outs and
endothelial cell specific CCM3
knock-outs possess yolk sacs which
lack a normal vascular tree, exhibit
developmental arrest at e9.5, develop an
enlarged pericardial region with
hemorrhage, abnormal branchial arch
development and lack normal dorsal aorta
patency proximal to the heart [49]. In
addition to the above findings, the CCM1
knock-out mice possessed dilated atria,

Figure 28 Primary astrocyte culture of
GFAP-Cre;Ccm3lox/lox brains were resistant
to cycloheximide induced apoptosis. Primary
astrocyte
cultures
were
exposed
to
cycloheximide (20μg/ml) for 3 hrs. Cells were
analysed for apoptosis by staining for Annexin
V. Flow cytometric analysis revealed fewer
GFAP-Cre;Ccm3lox/lox astrocytes (C and D)
entering apoptosis after 3 hrs exposure to
cycoheximide
compared
to
GFAPCre;Ccm3lox/+ astrocytes
(A
and
B).
Quantification of 13 primary astrocyte cultures
(6 GFAP-Cre;Ccm3lox/lox and 7 GFAPCre;Ccm3lox/+) lacked significance, but a trend
was present between GFAP-Cre;Ccm3lox/lox and
GFAP-Cre;Ccm3lox/+ cultures which underwent
treatment with cycloheximide (E). CCM3 +/- =
GFAP-Cre;Ccm3lox/+ , CCM3 -/- = GFAPCre;Ccm3lox/lox, +/- = GFAP-Cre;Ccm3lox/+ , -/= GFAP-Cre;Ccm3lox/lox, untreated = no
cycloheximide added to media, treated = media
with cycloheximide
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cranial vessels and caudal dorsal aorta.
Quantification of mitotic endothelial cells in
dilated vessels revealed increased endothelial cell
proliferation in dilated vasculature. CCM1
knock-out embryos lacked normal expression of
alpha-smooth muscle actin, an arterial marker.
Furthermore, immunohistochemical analysis of
Figure 29 A blocker of β1-integrin
signaling
cascade
attenuated
expression of Caspase-3. HUVECs
were cultured and allowed to grow to
confluence. Western blot analysis was
performed on cultures after a 3 day
exposure to a β1-integrin activating
antibody (TS2/16), a β1-integrin
blocking antibody (P4C10) and a Mouse
IgG control. The β1-integrin blocking
antibody (middle lane) significantly
reduced the expression of Caspase-3.

CCM1 knock-out mice revealed decreased
vascular expression of NOTCH4, which
corresponds to human CCM [49]. This data
further supports the hypothesis that CCM1 and
CCM3 share a common molecular pathway as
suggested by the similar phenotype in human

CCM. Unfortunately, the phenotype alone does not prove CCM3 involvement in the
CCM1 pathway. Knock-out mice of other genes important in vasculogenesis develop
similar phenotypes. Loss of function mutations in activin receptor-like kinase-1
(ACVRL1) are known to cause hereditary hemorrhagic telangectasia. Murine knock-outs
of ACVRL1 arrest at e9.5, lack an appropriate yolk sac vascular tree, display a dilated
cardiac region, possess dilated cardinal veins and are deficient of the arterial-specific
marker Efnb2 [50]. A mouse knock-out of vascular endothelial cell protein tyrosine
phosphatase, a modulator of Tie2, display arrested development at e9.5, exhibit primitive
yolk sac development (lacking a vascular tree), are significantly smaller than control
embryos, develop pericardial edema, and exhibit collapsed dorsal aorta [51]. This data
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raises the question of whether the phenotype our group has found is a common phenotype
when vasculogenesis is disrupted, or do the CCM’s play a role in Tie2 mediated
regulation of vascular modeling? The latter is supported by recent zebrafish experiments.
Zebrafish harboring mutations in the gene santa (san, homolog of krit1) resulted in
increased Tie2 expression, suggesting san/krit1 is a negative regulator of endothelial cell
gene expression. Zebrafish with the san mutation exhibit dilated vessels and an increase
in endothelial cells similar to that observed in CCM1 knock-out embryos. Additionally,
mutations of valentine (vtn, homolog of malcavernin) exhibit cardinal veins with
decreased luminal diameter [52]. Further studies on the endothelial cell specific CCM3
knockout mouse are necessary to conclude the extent of phenocopy to CCM1 knockouts.
CCM3 in Glial affects cortical layering
In our mouse model, mice deficient of CCM3 in GFAP expressing cell lines
exhibited severe difficulties with gait. Our nissl staining, in situ hybridization and
immunohistochemistry revealed a lack of normal cortical and cerebellar layering.
Although the cerebellar defects could account for the ataxia, this phenotype cannot be
conclusively traced to the cerebellum given the extent of abnormal development
throughout other brain regions, including the basal ganglia and somatosensory cortex.
The question arises as to what is the cause of the observed dysmorphism? We have
observed in previous experiments increased presence of GFAP signal in GFAPCre;CCM3lox/lox cortical sections. Does this represent an increased number of GFAP
positive cells? Our BrdU experiments suggest the contrary. Fewer dividing cells were
identified in the GFAP-Cre;CCM3lox/lox cortex. The observation of fewer dividing cells
may be explained by the decrease in neuronal migration as revealed by in situ
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hybridization. The cells which normally would be dividing in the cortex may never make
it out of the ventricular zone. Or could the increase in GFAP signal represent increased
astrocytic processes, since GFAP is an intermediate filament? It is possible that CCM3
modulates the extent and direction of glia process growth. A perturbation in this growth
may lead to aberrant glial processes. If this is correct, and what we have observed are
aberrant processes, this is suggestive of a problem in the normal communication glia
usually undergo with the surrounding environment of extracellular matrix, neurons and
endothelia. Moving forward, we will use TUNEL assays on cortical sections to observe
changes in apoptosis.
GFAP-Cre;CCM3lox/+ mice were the only available control mice for the BrdU
experiments. In future experiments, comparisons made between WT and GFAPCre;CCM3lox/lox mice may reveal a greater difference in BrdU labeling in somatosensory
cortex and possibly the visual cortex.
GFAP-Cre;CCM3lox/lox astrocyte cultures are resistant to apoptosis
We utilized flow activated cell sorting to observe apoptosis. This was the first
time our group has attempted this technique. This method has significant advantages to
other methods of observing apoptosis. With FACS we are able to observe the whole
culture. This decreases the incidence of a sampling error, which may occur when
choosing fields of a slide on which to perform counts. In the future, the use of FACS will
allow us to sort cells based on expression of cell markers. After sorting, these cells will
be used for RT-PCR and Western blotting to assess changes in expression of CCM
pathway modulators.
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In agreement with our previous PDCD10 siRNA experiments in HUVECs and
TUNEL assays performed on primary GFAP-Cre;CCM3lox/lox astrocytes exposed to
cycloheximide, GFAP-Cre;CCM3lox/lox astrocytes exhibit less expression of intracellular
phospholipids on their outer surface than control astrocytes three hours after exposure to
cycloheximide. We measured this expression of normally intracellular phospholipids by
annexin V staining, a known marker of early apoptosis. Although our data reveals a
trend towards resistance to apoptosis in the GFAP-Cre;CCM3lox/lox astrocytes,
significance was not achieved. This experiment was complicated by a number of factors.
Analysis of the FACS dot plots reveals that the vast majority of culture, control
and experimental, did not enter apoptosis after exposure to cycloheximide. There are at
least two explanations for this observation. We introduced cycloheximide to cultures
after the cultures had reached confluence. In other experiments using HUVECS, I have
noticed a decrease in how responsive cultures are to an intervention (antibody or
chemical) once allowed to grow to confluence. Cultures have been more responsive to
intervention when the intervention is performed on cultures around 70-80% confluence.
Future cycloheximide experiments should be performed before cultures reach confluence.
Another explanation is that too little cycloheximide was used to induce apoptosis. We
used 20 μg/ml of cycloheximide in culture to induce apoptosis. This concentration has
been shown to induce apoptosis in approximately 50% of wild-type primary rat astrocyte
cultures [53]. This is not terribly different from our ability to induce apoptosis in
approximately 38% of GFAP-Cre;CCM3lox/+ cultures. Increasing the concentration of
cycloheximide used under our conditions may induce apoptosis in a higher percentage of
the culture population. Unfortunately, heterozygous, GFAP-Cre;CCM3lox/+ , cultures
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were the only available controls for this set of experiments. It would be interesting to
investigate the difference between GFAP-Cre;CCM3lox/lox and WT cultures in response to
apoptotic stimuli.
Another complicating factor in our experiments was the lack of purity in our
astrocyte cultures. In many of our astrocyte cultures, immunohistochemistry for GFAP
and staining of DAPI revealed a significant population of cells which were not GFAP
positive. Our cultures were often contaminated with another cell type. The most
common contaminant in primary astrocyte cultures are fibroblasts. In our system,
fibroblasts from GFAP-Cre;CCM3lox/lox brains would normally express CCM3. These
cells may not be resistant to apoptosis, as CCM3 deficient cells seem to be. The
contamination of our cultures with fibroblast may have been responsible for the lack of
consistent results as evident by the error bars in figure 8.

β-1 integrin modulation changed expression of a modulator of caspase-3
The literature has implicated CCM1 in β-1 integrin signaling through interactions
with ICAP. Mounting evidence from our group and others suggest the CCM’s act by
modulating a common pathway and possibly as a complex. This present study further
supports this hypothesis based on the similarities of phenotype between CCM1 mutant
and our Tie2-CCM3 knock-outs. Additionally, our GFAP-Cre;CCM3lox/lox mice have
demonstrated cortical layering perturbations similar to that seen in β1-integrin mutants
[30].
To further pinpoint CCM3’s role in β1-integrin signaling it will be necessary to
be able to change β1-integrin signaling. This could be attempted by changing the
substrate on which astrocyte cultures will be grown or changing β1-integrin expression.
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The method we have chosen uses antibodies in cell culture to modify signaling of
endogenously expressed β1-integrin. The ability to use P4C10, a known blocker of β1integrin signaling, to attenuate caspase-3; coupled with the ability to utilize TS2/16, a
known potentiator of β1-integrin signaling, to increase caspase-3 expression will allow us
to further elucidate CCM3’s role in β1-integrin mediated apoptosis, cell migration,
adhesion and proliferation.

Conclusion
The above experiments further support the hypothesis that CCM3 is involved in a
signaling pathway common to CCM1 and CCM2. Our Cre;lox mouse model has
replicated human disease, producing CCM in the GFAP-Cre;CCM3lox/lox mouse, along
with the dilated vessels often accompanying human CCM. The findings in the GFAPCre;CCM3lox/lox mouse suggest that CCM3 is important in glia for the prevention of
CCM, as well as normal cortical development. Our mouse model differs from human
CCM in the fact that all GFAP positive cells present in the mouse CNS are deficient in
CCM3. In a two-hit hypothesis of familial human CCM, these cells would be
haploinsufficient. The acquisition of an additional, random mutation of the functional
allele could cause the development of CCM without gross abnormalities in cortical
development.
Future experiments could utilize a Cre-recombinase expressing adenovirus. This
virus injected into the CNS of Cre;CCM3lox/lox mice would afford us greater temporal and
spatial control of CCM3 attenuation. It would be interesting to see if this method would
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lead to CCM formation. It would also be interesting to know if loosing CCM3 function
and subsequent CCM formation is dependent on the stage of development.
Our mouse model, combined with primary cell cultures obtained from our mice,
has been useful in elucidating CCM3 function. With the discovery of a CCM in one of
the mutant mice, this system may be a useful model of human disease. Our methods will
continue to be useful in further clarifying the pathogenesis of cerebral cavernous
malformations.
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